Cancer Drugs Will Continue To Command High Prices, Scully Predicts
Executive Summary
The transformation in the Medicare market will not prevent cancer drugs from commanding very high prices, former Centers for Medicare & Medicaid Services Administrator Tom Scully predicted during the Washington Research Group's annual symposium Nov. 5